Cargando…

TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients

Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Eriza Cristina, Bittar, Camila Matzenbacher, Vianna, Fernanda Sales Luis, Netto, Cristina Brinckmann Oliveira, Biazús, Jorge Villanova, Cericatto, Rodrigo, Cavalheiro, José Antônio, de Melo, Márcia Portela, Menke, Carlos Henrique, Rabin, Eliane, Leistner-Segal, Sandra, Ashton-Prolla, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312227/
https://www.ncbi.nlm.nih.gov/pubmed/30596752
http://dx.doi.org/10.1371/journal.pone.0209934
_version_ 1783383738481115136
author Hahn, Eriza Cristina
Bittar, Camila Matzenbacher
Vianna, Fernanda Sales Luis
Netto, Cristina Brinckmann Oliveira
Biazús, Jorge Villanova
Cericatto, Rodrigo
Cavalheiro, José Antônio
de Melo, Márcia Portela
Menke, Carlos Henrique
Rabin, Eliane
Leistner-Segal, Sandra
Ashton-Prolla, Patricia
author_facet Hahn, Eriza Cristina
Bittar, Camila Matzenbacher
Vianna, Fernanda Sales Luis
Netto, Cristina Brinckmann Oliveira
Biazús, Jorge Villanova
Cericatto, Rodrigo
Cavalheiro, José Antônio
de Melo, Márcia Portela
Menke, Carlos Henrique
Rabin, Eliane
Leistner-Segal, Sandra
Ashton-Prolla, Patricia
author_sort Hahn, Eriza Cristina
collection PubMed
description Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1–1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93–5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios.
format Online
Article
Text
id pubmed-6312227
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63122272019-01-08 TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients Hahn, Eriza Cristina Bittar, Camila Matzenbacher Vianna, Fernanda Sales Luis Netto, Cristina Brinckmann Oliveira Biazús, Jorge Villanova Cericatto, Rodrigo Cavalheiro, José Antônio de Melo, Márcia Portela Menke, Carlos Henrique Rabin, Eliane Leistner-Segal, Sandra Ashton-Prolla, Patricia PLoS One Research Article Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1–1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93–5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios. Public Library of Science 2018-12-31 /pmc/articles/PMC6312227/ /pubmed/30596752 http://dx.doi.org/10.1371/journal.pone.0209934 Text en © 2018 Hahn et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hahn, Eriza Cristina
Bittar, Camila Matzenbacher
Vianna, Fernanda Sales Luis
Netto, Cristina Brinckmann Oliveira
Biazús, Jorge Villanova
Cericatto, Rodrigo
Cavalheiro, José Antônio
de Melo, Márcia Portela
Menke, Carlos Henrique
Rabin, Eliane
Leistner-Segal, Sandra
Ashton-Prolla, Patricia
TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title_full TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title_fullStr TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title_full_unstemmed TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title_short TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
title_sort tp53 p.arg337his germline mutation prevalence in southern brazil: further evidence for mutation testing in young breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312227/
https://www.ncbi.nlm.nih.gov/pubmed/30596752
http://dx.doi.org/10.1371/journal.pone.0209934
work_keys_str_mv AT hahnerizacristina tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT bittarcamilamatzenbacher tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT viannafernandasalesluis tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT nettocristinabrinckmannoliveira tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT biazusjorgevillanova tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT cericattorodrigo tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT cavalheirojoseantonio tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT demelomarciaportela tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT menkecarloshenrique tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT rabineliane tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT leistnersegalsandra tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients
AT ashtonprollapatricia tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients